NASDAQ
09.10.26 | 22:00
1,110 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | TELA Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| TELA BIO Aktie jetzt für 0€ handeln | |||||
| Mo | TELA Bio Says FDA Grants 510(k) Clearance For Liora Monofilament Scaffold Product | 1 | RTTNews | ||
| Mo | TELA Bio, Inc.: TELA Bio Announces 510(k) Clearance for Liora Monofilament Scaffold for Soft Tissue Reinforcement | 166 | GlobeNewswire (Europe) | MALVERN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio" or the "Company"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
| 29.09. | TELA Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.09. | TELA Bio, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 31.08. | TELA Bio COO/CFO Roberto Cuca steps down | 3 | Seeking Alpha | ||
| 31.08. | TELA Bio cuts 20% of workforce to reduce costs by $17M annually | 3 | Investing.com | ||
| 31.08. | TELA Bio, Inc.: TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative | 325 | GlobeNewswire (Europe) | MALVERN, Pa., Aug. 31, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio" or the "Company"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
| 31.08. | TELA Bio, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 11.08. | TELA Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 11.08. | TELA Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.08. | Tela Bio outlines 9- to 12-month sales ramp while withdrawing full-year revenue guidance | 1 | Seeking Alpha | ||
| 10.08. | TELA Bio GAAP EPS of -$0.20 misses by $0.03, revenue of $19.3M misses by $0.71M | 1 | Seeking Alpha | ||
| 04.08. | TELA Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 04.08. | TELA Bio names Heather Getz as CEO and Director | 1 | Seeking Alpha | ||
| 04.08. | TELA Bio Names Heather Getz CEO | 2 | RTTNews | ||
| 04.08. | TELA Bio appoints Heather Getz as chief executive officer | 1 | Investing.com | ||
| 04.08. | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.08. | TELA Bio, Inc.: TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director | 204 | GlobeNewswire (Europe) | MALVERN, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio" or the "Company"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
| 20.07. | TELA Bio, Inc.: TELA Bio to Announce Second Quarter 2026 Financial Results | 2 | GlobeNewswire (USA) |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 200,50 | -0,17 % | Moderna-Aktie: Steht der Ausbruch bevor? | Die Moderna-Aktie setzt ihre spektakuläre Erholung fort und notiert bei 190,01 US$. Damit hat der Kurs der Moderna-Aktie eine mehrjährige Widerstandszone überwunden. Der Ausbruch eröffnet technisch... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,920 | -0,13 % | Jim Cramer Explains His Hesitation Over Sarepta (SRPT) Therapeutics | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,151 | +3,61 % | Pacific Biosciences Collaborates With TychoBio For AI-powered RNA Data Creation; Shares Up | ||
| MYRIAD GENETICS | 3,844 | 0,00 % | Myriad Genetics, Inc.: Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology | SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH)... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 0,976 | -0,32 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026 | Phio invites individual and institutional investors as well as advisors and analysts, to attend online at www.VirtualInvestorConference.comKing of Prussia, Pennsylvania--(Newsfile Corp. - October 6... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 11,700 | 0,00 % | Chutes & Ladders-Vir looks to Liu to lead late-stage push | ||
| ENLIVEX | 0,200 | -13,04 % | Enlivex Ltd.: Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion | - As of July 18, 2026, net asset value (NAV1) per share was $66.16 - As of July 18, 2026, Enlivex held 79,550,593,122 RAIN tokens with a total value of approximately $1.1 billion2- Nes-Ziona... ► Artikel lesen | |
| CARIBOU BIOSCIENCES | 0,460 | 0,00 % | Caribou Biosciences, Inc.: Caribou Biosciences to Evaluate Strategic Alternatives | -- Company to evaluate strategic alternatives to maximize stockholder value -- -- Caribou plans to discontinue vispa-cel and CB-011 allogeneic CAR-T cell therapy programs -- -- Cash, cash equivalents... ► Artikel lesen | |
| BIOAFFINITY TECHNOLOGIES | 4,725 | 0,00 % | bioAffinity Technologies, Inc. - 8-K, Current Report | ||
| ARRIVENT BIOPHARMA | 16,710 | -0,12 % | Fierce Pharma Asia-Novartis' $7.8B mRNA deal; Shionogi's $2B buy; ArriVent's phase 3 flop | ||
| SURROZEN | 29,565 | -0,42 % | Surrozen, Inc.: Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema | First patient expected to be dosed in the DUET study in the fourth quarter of 2026 Milestone triggers second closing of March 2025 private placement expected to provide approximately $95.1M in gross... ► Artikel lesen | |
| FOGHORN THERAPEUTICS | 2,010 | +0,50 % | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities | Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader programCompany to focus resources on wholly owned pipeline, including a Selective... ► Artikel lesen | |
| ELUTIA | 0,823 | 0,00 % | Elutia Inc.: Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029 | Boston Scientific released the full $8 million holdback on schedule and with no claimsEscrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 259,86 | 0,00 % | Praxis Precision Medicine Q2 2026 Earnings Call Transcript | ||
| ERASCA | 16,030 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen |
Das Unternehmen TELA BIO INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,110 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELA BIO INC finden Sie auf Wallstreet Online.